Absci Corp. and M2gen have entered into a partnership to create new cancer medicines. Absci’s generative artificial intelligence drug creation platform will leverage M2gen’s clinical and molecular data set, ORIEN Avatar, to accelerate the creation of therapeutics for a range of malignancies and patient profiles.